OBJECTIVE: The purpose of this study was to describe the safety, tolerability, and efficacy of quetiapine monotherapy continued for up to 26-weeks in youth with schizophrenia or bipolarI disorder. METHODS:Medically healthy boys and girls with a baseline Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) diagnosis of schizophrenia (ages 13-17 years) or a manic episode of bipolarI disorder (ages 10-17 years) who participated in one of two acute, double-blind, placebo-controlled studies of immediate-releasequetiapine were potentially eligible to enroll in a 26-week, open-label study. During the open-label study, quetiapine was flexibly dosed at 400-800 mg/day, with options to reduce dosing to 200 mg/day based on tolerability. Safety and tolerability outcomes assessed from open-label baseline to week 26 included adverse events (AEs), metabolic/laboratory parameters, extrapyramidal symptoms, suicidality, and vital signs. RESULTS: Of 381 patients enrolled in the open-label study (n=176, schizophrenia; n=205, bipolar disorder diagnosis), 237 patients (62.2%) completed the 26-week study period (71.0%, schizophrenia; 54.6%, bipolar disorder). The most common AEs reported during the study included somnolence, headache, sedation, weight increase, and vomiting. A total of 14.9% of patients experienced a shift to potentially clinically significant low levels of high-density lipoprotein cholesterol and 10.2% of patients experienced a shift to potentially clinically significant high triglyceride levels. Weight gain ≥ 7% was reported in 35.6% of patients between open-label baseline and final visit. After adjustment for normal growth, 18.3% of study participants experienced clinically significant weight gain (i.e., increase in body mass index ≥ 0.5 standard deviations from baseline). CONCLUSIONS: In this 26-week study, quetiapine flexibly dosed at 400-800 mg/day, with options to reduce dosing based on tolerability, was generally safe and well tolerated in youth. Clinicians should monitor lipid profiles and weight gain in youth with schizophrenia or bipolar disorder during treatment withquetiapine.
RCT Entities:
OBJECTIVE: The purpose of this study was to describe the safety, tolerability, and efficacy of quetiapine monotherapy continued for up to 26-weeks in youth with schizophrenia or bipolar I disorder. METHODS: Medically healthy boys and girls with a baseline Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) diagnosis of schizophrenia (ages 13-17 years) or a manic episode of bipolar I disorder (ages 10-17 years) who participated in one of two acute, double-blind, placebo-controlled studies of immediate-release quetiapine were potentially eligible to enroll in a 26-week, open-label study. During the open-label study, quetiapine was flexibly dosed at 400-800 mg/day, with options to reduce dosing to 200 mg/day based on tolerability. Safety and tolerability outcomes assessed from open-label baseline to week 26 included adverse events (AEs), metabolic/laboratory parameters, extrapyramidal symptoms, suicidality, and vital signs. RESULTS: Of 381 patients enrolled in the open-label study (n=176, schizophrenia; n=205, bipolar disorder diagnosis), 237 patients (62.2%) completed the 26-week study period (71.0%, schizophrenia; 54.6%, bipolar disorder). The most common AEs reported during the study included somnolence, headache, sedation, weight increase, and vomiting. A total of 14.9% of patients experienced a shift to potentially clinically significant low levels of high-density lipoprotein cholesterol and 10.2% of patients experienced a shift to potentially clinically significant high triglyceride levels. Weight gain ≥ 7% was reported in 35.6% of patients between open-label baseline and final visit. After adjustment for normal growth, 18.3% of study participants experienced clinically significant weight gain (i.e., increase in body mass index ≥ 0.5 standard deviations from baseline). CONCLUSIONS: In this 26-week study, quetiapine flexibly dosed at 400-800 mg/day, with options to reduce dosing based on tolerability, was generally safe and well tolerated in youth. Clinicians should monitor lipid profiles and weight gain in youth with schizophrenia or bipolar disorder during treatment with quetiapine.
Authors: B J McConville; L A Arvanitis; P T Thyrum; C Yeh; L A Wilkinson; R O Chaney; K D Foster; M T Sorter; L M Friedman; K L Brown; J E Heubi Journal: J Clin Psychiatry Date: 2000-04 Impact factor: 4.384
Authors: Michael Berk; Karen Hallam; Gin S Malhi; Lisa Henry; Melissa Hasty; Craig Macneil; Murat Yucel; Chris Pantelis; Brendan Murphy; Eduard Vieta; Seetal Dodd; Patrick D McGorry Journal: J Ment Health Date: 2010-04
Authors: Mani N Pavuluri; David B Henry; Robert L Findling; Stephanie Parnes; Julie A Carbray; Tahseen Mohammed; Philip G Janicak; John A Sweeney Journal: Bipolar Disord Date: 2010-09 Impact factor: 6.744
Authors: David Fraguas; Christoph U Correll; Jessica Merchán-Naranjo; Marta Rapado-Castro; Mara Parellada; Carmen Moreno; Celso Arango Journal: Eur Neuropsychopharmacol Date: 2010-08-10 Impact factor: 4.600
Authors: Robert L Findling; Jacqueline L Johnson; Jon McClellan; Jean A Frazier; Benedetto Vitiello; Robert M Hamer; Jeffrey A Lieberman; Louise Ritz; Nora K McNamara; Jacqui Lingler; Stefanie Hlastala; Leslie Pierson; Madeline Puglia; Ann E Maloney; Emily Michael Kaufman; Nancy Noyes; Linmarie Sikich Journal: J Am Acad Child Adolesc Psychiatry Date: 2010-05-01 Impact factor: 8.829
Authors: Magali Haas; Alan S Unis; Jorge Armenteros; Margaret D Copenhaver; Jorge A Quiroz; Stuart F Kushner Journal: J Child Adolesc Psychopharmacol Date: 2009-12 Impact factor: 2.576
Authors: Andreas Reichert; Susanne Kreiker; Claudia Mehler-Wex; Andreas Warnke Journal: Child Adolesc Psychiatry Ment Health Date: 2008-02-27 Impact factor: 3.033
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk Journal: Bipolar Disord Date: 2018-03-14 Impact factor: 6.744
Authors: Caitlin S Yee; Emily R Hawken; Ross J Baldessarini; Gustavo H Vázquez Journal: Int J Neuropsychopharmacol Date: 2019-08-01 Impact factor: 5.176
Authors: Robert M Post; Benjamin I Goldstein; Boris Birmaher; Robert L Findling; Benicio N Frey; Melissa P DelBello; David J Miklowitz Journal: J Affect Disord Date: 2020-03-06 Impact factor: 4.839